MwanzoPRRUF • OTCMKTS
add
Immutep Ltd
Bei iliyotangulia
$ 0.18
Bei za mwaka
$ 0.17 - $ 0.28
Thamani ya kampuni katika soko
292.16M USD
Wastani wa hisa zilizouzwa
500.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
ASX
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (AUD) | Des 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.06M | 25.23% |
Matumizi ya uendeshaji wa biashara | 2.40M | 16.20% |
Mapato halisi | -10.61M | -2.93% |
Kiwango cha faida halisi | elfu -1.01 | 17.80% |
Mapato kwa kila hisa | — | — |
EBITDA | -11.10M | -8.28% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (AUD) | Des 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 103.73M | 51.71% |
Jumla ya mali | 123.79M | 43.92% |
Jumla ya dhima | 8.15M | -12.60% |
Jumla ya hisa | 115.64M | — |
hisa zilizosalia | 1.19B | — |
Uwiano wa bei na thamani | 1.83 | — |
Faida inayotokana na mali | -23.35% | — |
Faida inayotokana mtaji | -24.65% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (AUD) | Des 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -10.61M | -2.93% |
Pesa kutokana na shughuli | -9.23M | -54.83% |
Pesa kutokana na uwekezaji | elfu -209.56 | -607.90% |
Pesa kutokana na ufadhili | elfu -215.93 | -278.22% |
Mabadiliko halisi ya pesa taslimu | -9.84M | -69.40% |
Mtiririko huru wa pesa | -6.90M | -2.37% |
Kuhusu
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2001
Tovuti
Wafanyakazi
19
